Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials

R. M. Goldberg, C. Erlichman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Both fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States. Preclinical experiments in cell cultures and human tumor xenografts have indicated potential synergy when irinotecan is combined with 5-FU and leucovorin. The synergy appears to be sequence-dependent and is optimal when irinotecan exposure precedes 5-FU exposure by at least 24 hours. Four North American trials have been reported in which the three drugs were used together in either simultaneous, sequential, or alternating schedules. All three schedules showed activity in patients with metastatic colorectal cancer. The concern that diarrhea, which can be a dose-limiting toxicity with both irinotecan and 5-FU, would prevent the two drugs from being combined in reasonable doses has not proven to be a clinical issue. Phase III trials comparing the combination of the three drugs in a variety of schedules against 5-FU plus leucovorin alone are currently under way or in the planning stages.

Original languageEnglish (US)
Pages (from-to)59-63
Number of pages5
JournalOncology
Volume12
Issue number8 SUPPL.
StatePublished - 1998

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Appointments and Schedules
Drug Combinations
Heterografts
Pharmaceutical Preparations
Diarrhea
Cell Culture Techniques

ASJC Scopus subject areas

  • Oncology

Cite this

Goldberg, R. M., & Erlichman, C. (1998). Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Oncology, 12(8 SUPPL.), 59-63.

Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer : North American trials. / Goldberg, R. M.; Erlichman, C.

In: Oncology, Vol. 12, No. 8 SUPPL., 1998, p. 59-63.

Research output: Contribution to journalArticle

Goldberg, RM & Erlichman, C 1998, 'Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials', Oncology, vol. 12, no. 8 SUPPL., pp. 59-63.
Goldberg, R. M. ; Erlichman, C. / Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer : North American trials. In: Oncology. 1998 ; Vol. 12, No. 8 SUPPL. pp. 59-63.
@article{fcea551740a04bce87e92b0d5dc71eb0,
title = "Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials",
abstract = "Both fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States. Preclinical experiments in cell cultures and human tumor xenografts have indicated potential synergy when irinotecan is combined with 5-FU and leucovorin. The synergy appears to be sequence-dependent and is optimal when irinotecan exposure precedes 5-FU exposure by at least 24 hours. Four North American trials have been reported in which the three drugs were used together in either simultaneous, sequential, or alternating schedules. All three schedules showed activity in patients with metastatic colorectal cancer. The concern that diarrhea, which can be a dose-limiting toxicity with both irinotecan and 5-FU, would prevent the two drugs from being combined in reasonable doses has not proven to be a clinical issue. Phase III trials comparing the combination of the three drugs in a variety of schedules against 5-FU plus leucovorin alone are currently under way or in the planning stages.",
author = "Goldberg, {R. M.} and C. Erlichman",
year = "1998",
language = "English (US)",
volume = "12",
pages = "59--63",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "8 SUPPL.",

}

TY - JOUR

T1 - Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer

T2 - North American trials

AU - Goldberg, R. M.

AU - Erlichman, C.

PY - 1998

Y1 - 1998

N2 - Both fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States. Preclinical experiments in cell cultures and human tumor xenografts have indicated potential synergy when irinotecan is combined with 5-FU and leucovorin. The synergy appears to be sequence-dependent and is optimal when irinotecan exposure precedes 5-FU exposure by at least 24 hours. Four North American trials have been reported in which the three drugs were used together in either simultaneous, sequential, or alternating schedules. All three schedules showed activity in patients with metastatic colorectal cancer. The concern that diarrhea, which can be a dose-limiting toxicity with both irinotecan and 5-FU, would prevent the two drugs from being combined in reasonable doses has not proven to be a clinical issue. Phase III trials comparing the combination of the three drugs in a variety of schedules against 5-FU plus leucovorin alone are currently under way or in the planning stages.

AB - Both fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States. Preclinical experiments in cell cultures and human tumor xenografts have indicated potential synergy when irinotecan is combined with 5-FU and leucovorin. The synergy appears to be sequence-dependent and is optimal when irinotecan exposure precedes 5-FU exposure by at least 24 hours. Four North American trials have been reported in which the three drugs were used together in either simultaneous, sequential, or alternating schedules. All three schedules showed activity in patients with metastatic colorectal cancer. The concern that diarrhea, which can be a dose-limiting toxicity with both irinotecan and 5-FU, would prevent the two drugs from being combined in reasonable doses has not proven to be a clinical issue. Phase III trials comparing the combination of the three drugs in a variety of schedules against 5-FU plus leucovorin alone are currently under way or in the planning stages.

UR - http://www.scopus.com/inward/record.url?scp=0031793675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031793675&partnerID=8YFLogxK

M3 - Article

C2 - 9726093

AN - SCOPUS:0031793675

VL - 12

SP - 59

EP - 63

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 8 SUPPL.

ER -